STAT+: Up and down the ladder: The latest comings and goings
Stat News • 2/13/2026
Summary
The article titled "STAT+: Up and down the ladder: The latest comings and goings" reports on new hires, departures, promotions, and transfers within the pharmaceutical industry. It provides an overview of the latest changes in personnel in this sector.
Advertisement
Lindy Score Breakdown (V4.2)
49d
Age
1
Sources
from cluster
1181
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1181/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1181/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 49 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Up and down the ladder: The latest comings and goings
Stat News • Today
STAT+: ‘Takeover Tuesday’ saves biotech’s quarter
Stat News • 1 day ago
STAT+: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts
Stat News • 1 day ago
STAT+: Trump administration prepares 100% tariffs on some imported drugs
Stat News • 1 day ago
STAT+: Makary marks one year at FDA with focus on achievements in speech to staff
Stat News • 2 days ago
STAT+: Large AI scribe study finds modest time savings, inconsistent use
Stat News • 2 days ago
STAT+: Pharmalittle: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more
Stat News • 2 days ago
STAT+: Insilico Medicine CEO on how best to use AI in drug development
Stat News • 2 days ago
STAT+: Novo’s subscription model raises questions about pharma-telehealth tie-ups
Stat News • 2 days ago
STAT+: Government watchdog urges FDA to finalize guidance for advisory committee conflicts of interest
Stat News • 2 days ago
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago